Literature DB >> 25989361

Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.

Mark Boonyasampant1, Ilene C Weitz2, Brian Kay1, Chaiyaporn Boonchalermvichian2, Howard A Liebman2, Ira A Shulman1.   

Abstract

BACKGROUND: Hyperhemolysis in sickle cell disease is a rare and potentially life-threatening complication of transfusion. STUDY DESIGN AND METHODS: In this article we report a case of delayed hemolytic transfusion reaction with resultant hyperhemolysis triggered by an anti-IH autoantibody with alloantibody behavior.
RESULTS: The anti-IH was reactive at room temperature as well as 37 °C, but only weakly reactive with autologous red blood cells. Initial cold agglutinin titer was 512. The profound, life-threatening, intravascular hemolysis was rapidly and dramatically reduced with the Complement 5 (C5) inhibitory antibody, eculizumab. The auto/allo cold agglutinin was subsequently suppressed with rituximab treatment.
CONCLUSIONS: Eculizumab, a potent C5 inhibitory antibody, can be a rapid and effective therapy for hyperhemolytic transfusion reactions when given in a sufficient dose to fully block the activation of complement C5.
© 2015 AABB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25989361     DOI: 10.1111/trf.13144

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Incidental Discovery of Anti-IH in a Patient Planned for Caesarean Section and it's Repercussions.

Authors:  Lin-Nan Shao; Wen-Qian Song; Ni Wang; Wei-Jian Yu; Shi-Hang Zhou
Journal:  Indian J Hematol Blood Transfus       Date:  2017-11-18       Impact factor: 0.900

2.  Eculizumab as a Treatment for Hyper-Haemolytic and Aplastic Crisis in Sickle Cell Disease.

Authors:  Ishan Patel; Mihir Odak; Steven Douedi; Abbas Alshami; Vandan D Upadhyaya; Mohammad Hossain; Madhurima Anne; Swapnil V Patel
Journal:  Eur J Case Rep Intern Med       Date:  2021-08-07

3.  Delayed Severe Hemolytic Transfusion Reaction During Pregnancy in a Woman with β-Thalassemia Intermediate: Successful Outcome After Eculizumab Administration.

Authors:  Giovanna Cannas; Léa Dubreuil; Axel Fichez; Mathieu Gerfaud-Valentin; Anne-Lise Debard; Arnaud Hot
Journal:  Am J Case Rep       Date:  2021-05-13

4.  Red cell transfusion and alloimmunization in sickle cell disease.

Authors:  Grace E Linder; Stella T Chou
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

5.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

6.  Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease.

Authors:  Satheesh Chonat; Maa-Ohui Quarmyne; Caroline M Bennett; Christina L Dean; Clinton H Joiner; Ross M Fasano; Sean R Stowell
Journal:  Haematologica       Date:  2018-05-24       Impact factor: 11.047

Review 7.  Complement in Sickle Cell Disease: Are We Ready for Prime Time?

Authors:  Eleni Gavriilaki; Efthymia Vlachaki; Christos Varelas; Athina Tampaki; Ioanna Sakellari; Αchilles Anagnostopoulos
Journal:  J Blood Med       Date:  2021-03-23

8.  Hyperhemolysis in a patient with sickle cell disease and recent SARS-CoV-2 infection, with complex auto- and alloantibody work-up, successfully treated with tocilizumab.

Authors:  Christine Fuja; Vishesh Kothary; Timothy Clifford Carll; Savita Singh; Paul Mansfield; Geoffrey D Wool
Journal:  Transfusion       Date:  2022-05-30       Impact factor: 3.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.